La cadena de opciones muestra datos clave de las opciones de acciones de Prenetics Global a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Prenetics Global..

Prenetics Global (NASDAQ:PRE) Bolsa, Cadena de Opciones

PartnerRe

PartnerRe Ltd.

NYSE

Prenetics Global

Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global Ltd

Presearch

PRESTIGE CARS INTL by Prestige Cars International, Inc.

Prestige Cars International Inc

Predictive Technology Group Inc

PREDICTIVE TECH GROUP INC by Predictive Technology Group, Inc.

Principal Spectrum Preferred Securities Active ETF

PRECIPITATE GOLD CORP by Precipitate Gold Corp

Precipitate Gold Corp

PARTNERRE PFD SHS SER J by PartnerRe Ltd.

PartnerRe Ltd

PRAIRIESKY ROYALTY LTD by Prairiesky Royalty Ltd.

PrairieSky Royalty Ltd

PERPETUAL RES LTD ORD by Perpetual Resources Limited

Perpetual Resources Ltd

Pennsylvania Real Estate Investment Trust

Pennsylvania Real Estate Investment Trust 7 3/8 % Cum Red Perp Pfd Shs Series -B-

Pennsylvania Real Estate Investment Trust 7.20% Cum Red Perp Registered Pfd Shs Series -C-

Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D-

Prosperity Real Estate Investment Trust

POWER RESOURCE EXPL INC by Power Resource Exploration Inc.

Power Resource Exploration Inc

For the first quarter of 2025, we expect consumer results to be:
<ul>
<li>Revenue of $11.5 million to $13 million
<ul>
<li>IM8: $4.0 million to $4.5 million</li>
<li>Europa: $5.0 million to $5.5 million</li>
<li>CircleDNA: $2.5 million to $3.0 million</li>
</ul>
</li>
<li>Adjusted EBITDA loss: $(5.5) million to $(6.0) million</li>
</ul>
For the full year 2025, we expect consumer results to be:
<ul>
<li>Revenue of $73 million to $85 million
<ul>
<li>IM8: $30 million to $35 million</li>
<li>Europa: $30 million to $35 million</li>
<li>CircleDNA: $13 million to $15 million</li>
</ul>
</li>
<li>Adjusted EBITDA loss: $(13) million to $(15) million</li>
<li>Q4 2025: Adjusted EBITDA profitable</li>
</ul>

News

Guidance

Prenetics Sees Q1 Revenue $11.5M-$13M Vs $11.2M Est.; FY25 Revenue $73M-$85M Vs $75.4M Est.

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly sales of $10.500 million which missed the analyst consensus estimate of $12.400 million by 15.32 percent. This is a 93.43 percent increase over sales of $5.428 million the same period last year.

Earnings

Earnings Misses

Prenetics Global Q4 Sales $10.500M Miss $12.400M Estimate

<ul>
<li>CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraise</li>
<li>Prenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheet</li>
<li>Prenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Prenetics Partners With Humanity Protocol And Launches Crypto Strategic Reserve; Prenetics Invests $1.5M In Bitcoin, Solana And H Tokens

Cantor Fitzgerald analyst Ross Osborn reiterates Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) with a Overweight and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Prenetics Global, Maintains $9 Price Target

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness
IM8, a New Premium Supplements Brand, Launched Officially on November 18th on <a href="https://www.globenewswire.com/Tracker?data=91rCEEadc0RFBygsq67dhEX6Z46j795crsPTx5gKFdBflK5_xqn18v7qVbxs43xMs60CoK0igxLWo80JDhtvNg==">IM8health.com</a>
CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics' (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. This collaboration aims to advance health and longevity through the fusion of IM8's cutting-edge innovation and Mayo Clinic's medical expertise.
The collaboration will focus on creating evidence-based, clinically researched supplements designed to address key health priorities such as optimal nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall well-being. The work seeks to ensure that every product developed meets the highest standards of science and efficacy, empowering individuals to take charge of their health with confidence.

Biotech

General

Prenetics' IM8 Announces Collaboration With Mayo Clinic To Develop New Line Of Premium Supplements To Focus On Nutrition, Cellular Rejuvenation, Protein, Collagen And Overall Wellness

Mission Aims To Enhance Healthspan On Earth And Astronaut Health In Space, Leveraging Microgravity For Cellular Research And Autophagy Insights

Prenetics' IM8 And University Of Oxford Launch Space Experiment On ISS To Study Accelerated Aging And Longevity

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported its Q3 earnings results on Wednesday, November 27, 2024 at 08:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Prenetics Global beat estimated earnings by 2.0%, reporting an EPS of $-0.84 versus an estimate of $-0.86.
Revenue was up $2.91 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.05, resulting in a 9.0% drop change in the share price the following day.

To track all earnings releases for Prenetics Global <a href="https://www.benzinga.com/quote/PRE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prenetics Global: Q3 Earnings Insights

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent. This is a 4.55 percent increase over losses of $(0.88) per share from the same period last year. The company reported $7.78 million in sales this quarter. This is a 30.91 percent increase over sales of $5.94 million the same period last year.

Prenetics Global Q3 EPS $(0.84) Beats $(0.86) Estimate, Sales $7.78M Up From $5.94M YoY

Health Care

Prenetics In Partnership With David Beckham, Announced The Official Launch Of IM8, A Health And Wellness Brand that Introduces Two Premium Products, Daily Ultimate Essentials, And Daily Ultimate Longevity, Both Now Available For Purchase At IM8Health.Com, With Shipping To 31 Countries, Including Free Shipping To US, UK, Canada, Singapore, And Hong Kong

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 89.0% to $1.43 during Tuesday's regular session. The company's market cap stands at $14.4 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 29.25% to $0.07. The company's market cap stands at $8.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 20.69% to $8.34. The market value of their outstanding shares is at $49.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares increased by 20.43% to $2.41. The company's market cap stands at $71.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 19.81% to $5.26. The market value of their outstanding shares is at $64.2 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock moved upwards by 18.36% to $3.03. The market value of their outstanding shares is at $16.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares declined by 45.3% to $1.34 during Tuesday's regular session. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 15.93% to $0.27. The company's market cap stands at $5.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 15.26% to $2.69. The company's market cap stands at $78.9 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 15.08% to $26.59. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 14.73% to $2.2. The market value of their outstanding shares is at $4.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares decreased by 14.69% to $3.83. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APRE

CDNA

DWTX

GRTS

IMRX

MYNZ

NIVF

RANI

RBOT

SEEL

XCUR

12 Health Care Stocks Moving In Tuesday's Intraday Session

WIIM

Prenetics Global shares are trading higher following the announcement that Tencent made a $30 million investment in Insighta.

Financing

Prenetics Global Announces Tencent's $30M Investment in Insighta

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.93) by 5.38 percent. This is a 25.71 percent decrease over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $5.94 million which missed the analyst consensus estimate of $7.70 million by 22.84 percent. This is a 8.75 percent decrease over sales of $6.51 million the same period last year.

Earnings Beats

Prenetics Global Q2 EPS $(0.88) Beats $(0.93) Estimate, Sales $5.94M Miss $7.70M Estimate

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly sales of $5.900 million which missed the analyst consensus estimate of $7.700 million by 23.38 percent. This is a 3.58 percent increase over sales of $5.696 million the same period last year.

Prenetics Global Q2 Sales $5.900M Miss $7.700M Estimate

<h3>Gainers</h3>
<ul>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock increased by 7.9% to $5.18 during Friday's after-market session. The market value of their outstanding shares is at $63.2 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares rose 5.39% to $0.67. The market value of their outstanding shares is at $3.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.3% to $1.39. The company's market cap stands at $2.5 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock moved upwards by 4.99% to $0.75. The market value of their outstanding shares is at $29.6 million. </li>
<li>Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) shares rose 4.8% to $3.93. The market value of their outstanding shares is at $314.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares rose 4.76% to $2.2. The company's market cap stands at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 42.5% to $2.65 during Friday's after-market session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 16.63% to $0.5. The market value of their outstanding shares is at $1.6 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 14.25% to $0.34. The market value of their outstanding shares is at $12.1 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares fell 10.12% to $0.4. The market value of their outstanding shares is at $11.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 9.63% to $0.36. The company's market cap stands at $7.4 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 6.77% to $0.43. The company's market cap stands at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCD

CHRO

CTCX

ENTO

INKT

KZIA

NKGN

NUWE

SLXN

THAR

TRVN

12 Health Care Stocks Moving In Friday's After-Market Session

Prenetics Global Limited shares are trading higher after the company announced the acquisition of Europa Sports Partners and its subsidiary, Hubmatrix.

Prenetics Global Acquires Europa Sports Partners And Hubmatrix To Accelerate Expansion Into U.S. Consumer Health And Wellness Market; Acquisition Supports IM8 Brand Co-Founded By David Beckham, Projecting Over $100M Revenue In FY2025

On Thursday, Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) announced that former international footballer, entrepreneur, and philanthropist David Beckham has become a strategic investor in the business.
Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1876431/000162828024031643/ex991.htm" rel="noreferrer noopener">focus</a> on consumer health products, with details to be announced at a later date.
Beckham said, &#8220;Throughout my life and career, I&#8217;ve been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That&#8217;s why I am excited to be working with Prenetics—a company dedicated to innovative, world-leading scientific advancements in health—as a co-founding partner and ambassador for IM8.&#8221;
Prenetics is a health sciences company. IM8, a new health and wellness brand, leads consumer initiatives.
The clinical division is led by Insighta, a $200 million joint venture with renowned scientist Prof. Dennis Lo, focused on multi-cancer early detection technologies.
Prenetics reported first-quarter revenue of $6.4 million, an increase of 30.2% compared <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39377509/prenetics-announces-first-quarter-2024-financial-results" rel="noreferrer noopener">to the first quarter of 2023</a>.
Danny Yeung, CEO and Co-Founder of Prenetics, remarked: &#8220;The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit&#8230;Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness.&#8221;
The company reported cash and other short-term assets&nbsp;of $86.6 million as of March 31, 2024.
Price Action: PRE shares are up 1.01% at $6.06 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39726263/exclusive-vivani-medical-outlines-plans-to-kickstart-first-clinical-study-for-miniature-glp-1-obe" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year</a></li>
</ul>
Photo via Shutterstock

Media

Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics

Prenetics, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) a leading health sciences company, is proud to&nbsp;announce&nbsp;that former international footballer, entrepreneur and philanthropist David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on cutting-edge consumer health products, with details to be announced at a later date.
Beckham said, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts and fitness coaches. Their guidance has been crucial to my health and well-being. That's why I am excited to be working with Prenetics - a company that is dedicated to innovative, world-leading scientific advancements in health - as a co-founding partner and ambassador for IM8."

Prenetics Partners With David Beckham As Co-Found Partners For IM8, A New Health And Wellness Brand

Press Releases

Prenetics Announces Participation in December Investor Conferences

Prenetics' IM8 and University of Oxford Begin Groundbreaking Space Experiment to Study Accelerated Aging and Longevity on the ISS with SpaceX, Supported by Space Applications Services

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Sports

Prenetics' IM8 Achieves Prestigious NSF Certified for Sport® for Daily Ultimate Essentials

Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David Beckham

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance

Prenetics to Participate in the 37th Annual ROTH Conference

Management

Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Prenetics Global

Prenetics Global (PRE) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL